Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SenesTech develops and commercializes ContraPest, a fertility control product for rat populations targeting commercial, municipal, and agricultural markets. The company operates a capital-light biotech model focused on pest management through reproductive inhibition rather than traditional rodenticides, positioning itself as an alternative to conventional pest control methods in urban environments and food production facilities.
SenesTech generates revenue by selling ContraPest, a liquid bait containing fertility inhibitors (triptolide-based compounds) that reduce rat reproduction rates. The company targets high-density rat environments where traditional rodenticides face resistance or regulatory restrictions. Pricing power derives from differentiation as a non-lethal solution with lower secondary poisoning risks. The 54% gross margin reflects manufacturing costs for active ingredients and formulation, while the -337% operating margin indicates the company remains in commercial scaling phase with substantial R&D, regulatory compliance, and sales infrastructure costs exceeding current revenue base. The business model requires customer education and field trial validation to demonstrate ROI versus conventional methods.
New commercial customer wins or multi-year contract announcements with major pest management operators or municipal accounts
Quarterly product sales volume and revenue growth rates, particularly acceleration beyond current 56% YoY growth trajectory
Regulatory developments including EPA label expansions, state-level approvals, or international registrations (EU, Asia-Pacific markets)
Cash burn rate and runway updates given negative operating cash flow and small market cap requiring potential capital raises
Peer-reviewed efficacy studies or field trial results demonstrating ROI metrics for commercial customers
Regulatory pathway uncertainty for fertility control products as EPA and state agencies evolve pesticide frameworks, with potential label restrictions or additional efficacy requirements increasing compliance costs
Technological adoption barriers as pest management industry remains conservative, favoring proven rodenticide methods over novel fertility control approaches requiring longer-term ROI demonstration periods
Competitive threat from next-generation rodenticides, genetic pest control technologies (gene drive systems), or integrated pest management platforms that could offer superior economics or efficacy
Incumbent rodenticide manufacturers (BASF, Syngenta, Liphatech) defending market share through pricing pressure or developing competing fertility control formulations
Customer switching costs remain low as pest management operators can revert to conventional methods if ContraPest fails to demonstrate sustained efficacy or economic advantage in field conditions
Liquidity risk given negative $3.8M operating cash flow (estimated based on margins) and micro-cap status limiting access to institutional capital, requiring equity raises that dilute existing shareholders at depressed valuations
Going concern risk if revenue growth fails to accelerate while operating losses persist, with current cash burn rate potentially requiring financing within 12-18 months based on 15.75x current ratio but minimal revenue base
moderate - Pest management spending exhibits defensive characteristics as food safety regulations and public health concerns drive baseline demand regardless of economic conditions. However, commercial real estate activity, restaurant openings, and food processing facility expansions correlate with GDP growth and influence new customer adoption. Municipal budget constraints during recessions could delay public sector contracts, while agricultural customers face commodity price sensitivity affecting capital allocation to pest management solutions.
Rising rates create dual pressures: higher discount rates compress valuation multiples for pre-profitable biotech companies, while increased financing costs affect the company's ability to raise growth capital on favorable terms. The 15.75x current ratio provides liquidity buffer, but sustained losses require periodic capital raises where rate environment influences equity dilution terms. Customer financing decisions show minimal rate sensitivity as pest management represents operational expense rather than capital investment.
Minimal direct credit exposure given B2B sales model with short receivable cycles to established pest management operators. However, the company's own access to capital markets matters significantly - tightening credit conditions reduce investor appetite for cash-burning micro-cap biotech stocks, potentially forcing dilutive financing or constraining growth investment. Customer credit quality matters less given the fragmented pest management industry structure and municipal customer base.
growth - The stock attracts speculative biotech investors focused on disruptive pest management technology with asymmetric upside if commercial adoption inflects. The 56% revenue growth, 92% EPS growth (off negative base), and early-stage commercialization profile appeal to investors willing to accept binary outcomes and high volatility. The -57% six-month return and micro-cap status indicate this is a high-risk, high-conviction position for investors betting on regulatory tailwinds (rodenticide restrictions) and urban rat population growth driving ContraPest adoption.
high - Micro-cap biotech with minimal revenue base, ongoing losses, and binary catalysts (contract wins, regulatory decisions, financing events) creates extreme volatility. The -27% to -57% drawdowns over trailing periods reflect illiquidity and sentiment-driven trading. Beta likely exceeds 2.0x given the speculative growth profile and small float susceptible to momentum swings on news flow.